Do GLP-1 Medications Pay for Themselves?
Add to Calendar! Glucagon-like peptide-1 receptor agonists (GLP-1s) represent a major improvement in treatment of diabetes, obesity, and cardiovascular risk reduction, but they are also among the most expensive drugs in widespread use and the subject of significant policy debate. The high price of these drugs may overstate their net cost if the health improvements […]
